Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1940 1
1947 1
1963 2
1964 3
1965 2
1966 2
1967 3
1970 5
1971 1
1972 4
1973 1
1974 2
1976 3
1978 1
1979 3
1980 5
1981 5
1982 2
1983 3
1984 2
1985 4
1986 4
1987 3
1988 3
1989 2
1990 3
1991 1
1992 5
1993 4
1994 12
1995 3
1996 7
1997 17
1998 9
1999 10
2000 5
2001 9
2002 8
2003 11
2004 8
2005 16
2006 17
2007 12
2008 19
2009 15
2010 11
2011 10
2012 9
2013 13
2014 7
2015 22
2016 17
2017 13
2018 14
2019 12
2020 5
2021 8
2022 7
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Tamura K, et al. Among authors: redman ra. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047803 Clinical Trial.
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Harrington KJ, et al. Among authors: redman r. JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147. JAMA Oncol. 2023. PMID: 37022706 Free PMC article.
Street outreach triptych.
Redman R. Redman R. Fam Syst Health. 2020 Mar;38(1):91. doi: 10.1037/fsh0000461. Fam Syst Health. 2020. PMID: 32202838
Fungal endophytes: diversity and functional roles.
Rodriguez RJ, White JF Jr, Arnold AE, Redman RS. Rodriguez RJ, et al. Among authors: redman rs. New Phytol. 2009;182(2):314-330. doi: 10.1111/j.1469-8137.2009.02773.x. Epub 2009 Feb 19. New Phytol. 2009. PMID: 19236579 Free article. Review.
Myoepithelium of salivary glands.
Redman RS. Redman RS. Microsc Res Tech. 1994 Jan 1;27(1):25-45. doi: 10.1002/jemt.1070270103. Microsc Res Tech. 1994. PMID: 8155903 Review.
Overview of seizure-inducing potential of doripenem.
Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R. Zhanel GG, et al. Among authors: redman r. Drug Saf. 2009;32(9):709-16. doi: 10.2165/00002018-200932090-00001. Drug Saf. 2009. PMID: 19670912 Review.
Iseganan HCl: a novel antimicrobial agent.
Giles FJ, Redman R, Yazji S, Bellm L. Giles FJ, et al. Among authors: redman r. Expert Opin Investig Drugs. 2002 Aug;11(8):1161-70. doi: 10.1517/13543784.11.8.1161. Expert Opin Investig Drugs. 2002. PMID: 12150709 Review.
389 results